BE1013214A6 - Procede de conversion de stereo-isomeres de sertraline en sertraline. - Google Patents
Procede de conversion de stereo-isomeres de sertraline en sertraline. Download PDFInfo
- Publication number
- BE1013214A6 BE1013214A6 BE2001/0440A BE200100440A BE1013214A6 BE 1013214 A6 BE1013214 A6 BE 1013214A6 BE 2001/0440 A BE2001/0440 A BE 2001/0440A BE 200100440 A BE200100440 A BE 200100440A BE 1013214 A6 BE1013214 A6 BE 1013214A6
- Authority
- BE
- Belgium
- Prior art keywords
- sertraline
- mixture
- imine
- trans
- cis
- Prior art date
Links
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 title claims abstract description 120
- 229960002073 sertraline Drugs 0.000 title claims abstract description 120
- 238000000034 method Methods 0.000 title claims abstract description 99
- 239000000203 mixture Substances 0.000 claims abstract description 83
- 150000002466 imines Chemical group 0.000 claims abstract description 69
- 238000006243 chemical reaction Methods 0.000 claims abstract description 16
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 8
- 238000001640 fractional crystallisation Methods 0.000 claims abstract description 5
- 239000002585 base Substances 0.000 claims description 25
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 18
- -1 halogen ions Chemical class 0.000 claims description 18
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 15
- 238000004064 recycling Methods 0.000 claims description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 13
- 238000006317 isomerization reaction Methods 0.000 claims description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 9
- 238000009903 catalytic hydrogenation reaction Methods 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 229910052751 metal Inorganic materials 0.000 claims description 8
- 239000002184 metal Substances 0.000 claims description 8
- 239000003586 protic polar solvent Substances 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 7
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 6
- 229910052783 alkali metal Inorganic materials 0.000 claims description 6
- HUCVOHYBFXVBRW-UHFFFAOYSA-M caesium hydroxide Chemical compound [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 claims description 6
- 230000000269 nucleophilic effect Effects 0.000 claims description 5
- 150000007530 organic bases Chemical class 0.000 claims description 5
- 230000003647 oxidation Effects 0.000 claims description 5
- 238000007254 oxidation reaction Methods 0.000 claims description 5
- 150000008044 alkali metal hydroxides Chemical class 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- CUQOHAYJWVTKDE-UHFFFAOYSA-N potassium;butan-1-olate Chemical group [K+].CCCC[O-] CUQOHAYJWVTKDE-UHFFFAOYSA-N 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000007868 Raney catalyst Substances 0.000 claims description 3
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 claims description 3
- 229910000564 Raney nickel Inorganic materials 0.000 claims description 3
- 150000001298 alcohols Chemical class 0.000 claims description 3
- 229910000288 alkali metal carbonate Inorganic materials 0.000 claims description 3
- 150000008041 alkali metal carbonates Chemical class 0.000 claims description 3
- 150000004703 alkoxides Chemical class 0.000 claims description 3
- 238000002955 isolation Methods 0.000 claims description 3
- ZJHSRWNUEOUFAZ-UHFFFAOYSA-N BrC1C(=O)NC(C1)=O.[N] Chemical group BrC1C(=O)NC(C1)=O.[N] ZJHSRWNUEOUFAZ-UHFFFAOYSA-N 0.000 claims description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- ZQQRVADLKUYTKD-UHFFFAOYSA-N ClC1C(=O)NC(C1)=O.[N] Chemical compound ClC1C(=O)NC(C1)=O.[N] ZQQRVADLKUYTKD-UHFFFAOYSA-N 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 2
- 150000003333 secondary alcohols Chemical class 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 150000003509 tertiary alcohols Chemical class 0.000 claims description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- FIPWRIJSWJWJAI-UHFFFAOYSA-N Butyl carbitol 6-propylpiperonyl ether Chemical group C1=C(CCC)C(COCCOCCOCCCC)=CC2=C1OCO2 FIPWRIJSWJWJAI-UHFFFAOYSA-N 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical group [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229960005235 piperonyl butoxide Drugs 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 125000000075 primary alcohol group Chemical group 0.000 claims 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 26
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 24
- 150000001412 amines Chemical class 0.000 description 13
- RZPFVRFSYMUDJO-UHFFFAOYSA-N 2h-naphthalen-1-one Chemical compound C1=CC=C2C(=O)CC=CC2=C1 RZPFVRFSYMUDJO-UHFFFAOYSA-N 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 9
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 150000003840 hydrochlorides Chemical class 0.000 description 6
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 5
- 150000002576 ketones Chemical class 0.000 description 5
- TYEYBOSBBBHJIV-UHFFFAOYSA-N 2-oxobutanoic acid Chemical compound CCC(=O)C(O)=O TYEYBOSBBBHJIV-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229960004592 isopropanol Drugs 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene-acid Natural products C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- MGBVAZJASCWJGJ-GFCCVEGCSA-N (4r)-4-(3,4-dichlorophenyl)-n-methyl-3,4-dihydro-2h-naphthalen-1-imine Chemical compound C1([C@H]2CCC(C3=CC=CC=C32)=NC)=CC=C(Cl)C(Cl)=C1 MGBVAZJASCWJGJ-GFCCVEGCSA-N 0.000 description 2
- RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-dichlorobenzene Chemical compound ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000000010 aprotic solvent Substances 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- LLUPHTAYNHAVQT-UHFFFAOYSA-N (3,4-dichlorophenyl)-phenylmethanone Chemical compound C1=C(Cl)C(Cl)=CC=C1C(=O)C1=CC=CC=C1 LLUPHTAYNHAVQT-UHFFFAOYSA-N 0.000 description 1
- KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical compound C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 description 1
- VCVUNRNRXFHPQB-UHFFFAOYSA-N 2,3-dichloro-3-phenylprop-2-enoic acid Chemical compound OC(=O)C(Cl)=C(Cl)C1=CC=CC=C1 VCVUNRNRXFHPQB-UHFFFAOYSA-N 0.000 description 1
- GLQPTZAAUROJMO-UHFFFAOYSA-N 4-(3,4-dimethoxyphenyl)benzaldehyde Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC=C(C=O)C=C1 GLQPTZAAUROJMO-UHFFFAOYSA-N 0.000 description 1
- INJJJPGJHRMABC-UHFFFAOYSA-N C(CCC)OCCCC.[K] Chemical group C(CCC)OCCCC.[K] INJJJPGJHRMABC-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010016275 Fear Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- JGDFBJMWFLXCLJ-UHFFFAOYSA-N copper chromite Chemical compound [Cu]=O.[Cu]=O.O=[Cr]O[Cr]=O JGDFBJMWFLXCLJ-UHFFFAOYSA-N 0.000 description 1
- 150000004292 cyclic ethers Chemical class 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000012804 iterative process Methods 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- BDOLXPFAFMNDOK-UHFFFAOYSA-N oxazaborolidine Chemical class B1CCON1 BDOLXPFAFMNDOK-UHFFFAOYSA-N 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 239000010970 precious metal Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000006798 ring closing metathesis reaction Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229960003660 sertraline hydrochloride Drugs 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 150000003738 xylenes Chemical class 0.000 description 1
- 229940020965 zoloft Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/68—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pain & Pain Management (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN12MU2000 IN187170B (enExample) | 2000-01-04 | 2000-01-04 | |
| US09/709,812 US6506940B1 (en) | 2000-01-04 | 2000-11-10 | Process for converting stereoisomers of sertraline into sertraline |
| CH01496/01A CH692620A5 (de) | 2000-01-04 | 2001-01-01 | Verfahren zur Umwandlung von Sertralin-Stereoisomeren in Sertralin. |
| AU35979/01A AU3597901A (en) | 2000-01-04 | 2001-01-01 | A process for converting stereoisomers of sertraline into sertraline |
| PCT/IN2001/000001 WO2001049638A2 (en) | 2000-01-04 | 2001-01-01 | A process for converting stereoisomers of sertraline into sertraline |
| IT2001MI000011A ITMI20010011A1 (it) | 2000-01-04 | 2001-01-04 | Processo per convertire stereoiosomeri di sertralina in sertralina |
| BE2001/0440A BE1013214A6 (fr) | 2000-01-04 | 2001-07-03 | Procede de conversion de stereo-isomeres de sertraline en sertraline. |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN12MU2000 IN187170B (enExample) | 2000-01-04 | 2000-01-04 | |
| US09/709,812 US6506940B1 (en) | 2000-01-04 | 2000-11-10 | Process for converting stereoisomers of sertraline into sertraline |
| BE2001/0440A BE1013214A6 (fr) | 2000-01-04 | 2001-07-03 | Procede de conversion de stereo-isomeres de sertraline en sertraline. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE1013214A6 true BE1013214A6 (fr) | 2001-10-02 |
Family
ID=27159887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE2001/0440A BE1013214A6 (fr) | 2000-01-04 | 2001-07-03 | Procede de conversion de stereo-isomeres de sertraline en sertraline. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US6506940B1 (enExample) |
| AU (1) | AU3597901A (enExample) |
| BE (1) | BE1013214A6 (enExample) |
| CH (1) | CH692620A5 (enExample) |
| IN (1) | IN187170B (enExample) |
| IT (1) | ITMI20010011A1 (enExample) |
| WO (1) | WO2001049638A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6723878B2 (en) | 2001-06-15 | 2004-04-20 | Orion Corporation Fermion | Method for preparing sertraline |
| US8134029B2 (en) | 2002-09-16 | 2012-03-13 | Sunovion Pharmaceuticals Inc. | Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine |
| WO2004092110A2 (en) * | 2003-04-14 | 2004-10-28 | Teva Pharmaceutical Industries Ltd. | Hydrogenation of imine intermediates of sertraline with catalysts |
| CA2536073A1 (en) * | 2003-08-18 | 2005-02-24 | H. Lundbeck A/S | Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine |
| WO2005023752A2 (en) * | 2003-09-05 | 2005-03-17 | Teva Pharmaceutical Industries Ltd. | A recycling process for preparing sertraline |
| JP2008530039A (ja) * | 2005-02-16 | 2008-08-07 | ハー・ルンドベック・アクチエゼルスカベット | トランス−１−（（１ｒ，３ｓ）−６−クロロ−３−フェニルインダン−１−イル）−３，３−ジメチルピペラジンの酒石酸塩およびリンゴ酸塩 |
| TWI376373B (en) * | 2005-02-16 | 2012-11-11 | Lundbeck & Co As H | Crystalline base of a pharmaceutical compound |
| TWI453198B (zh) * | 2005-02-16 | 2014-09-21 | Lundbeck & Co As H | 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s）-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法 |
| US7345201B2 (en) * | 2005-02-23 | 2008-03-18 | Teva Pharmaceutical Industries, Ltd. | Processes for preparing sertraline |
| EP1851189A1 (en) * | 2005-02-23 | 2007-11-07 | Teva Pharmaceutical Industries Ltd | Processes for preparing sertraline |
| WO2006129324A2 (en) | 2005-06-03 | 2006-12-07 | Hetero Drugs Limited | A highly stereoselective synthesis of sertraline |
| WO2007006003A2 (en) | 2005-07-06 | 2007-01-11 | Sepracor Inc. | Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders |
| DK2816024T3 (en) | 2006-03-31 | 2017-10-30 | Sunovion Pharmaceuticals Inc | CHIRALE AMINER |
| WO2009019412A1 (en) * | 2007-08-09 | 2009-02-12 | Npil Pharmaceuticals (Uk) Limited | Racemisation process for obtaining (1s,4s) n-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthaleneamine (sertraline) |
| MX2010012037A (es) * | 2008-05-07 | 2010-11-30 | Lundbeck & Co As H | Composiciones y uso utiles para tratar trastornos cognitivos. |
| JP2012504560A (ja) * | 2008-10-03 | 2012-02-23 | ハー・ルンドベック・アクチエゼルスカベット | 経口製剤 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4536518A (en) | 1979-11-01 | 1985-08-20 | Pfizer Inc. | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine |
| US4556676A (en) | 1979-11-01 | 1985-12-03 | Pfizer Inc. | Antidepressant derivatives of trans-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine |
| US4839104A (en) | 1987-06-11 | 1989-06-13 | Pfizer, Inc. | Process for preparing sertraline intermediates |
| US4777288A (en) | 1987-06-11 | 1988-10-11 | Pfizer Inc. | Process for preparing a 4,4-diphenylbutanoic acid derivative |
| US4855500A (en) | 1988-05-04 | 1989-08-08 | Pfizer Inc. | Process for preparing a ketimine |
| US5082970A (en) * | 1991-03-06 | 1992-01-21 | Pfizer Inc. | Process for recycling amine isomer |
| US5196607A (en) | 1992-02-14 | 1993-03-23 | Pfizer Inc. | Process for preparing ketone enantiomer |
| US5466880A (en) | 1992-09-15 | 1995-11-14 | Pfizer Inc. | Process for preparing ketone enantiomer |
| EP0724552B1 (en) | 1993-11-30 | 1997-10-29 | Pfizer Inc. | Process for preparing a chiral tetralone |
| HU218599B (hu) | 1996-10-09 | 2000-10-28 | EGIS Gyógyszergyár Rt. | Eljárás 4-(3,4-diklór-fenil)-3,4-dihidro-1-(2H)-naftalin-1-on előállítására |
| HU222341B1 (hu) | 1996-12-18 | 2003-06-28 | Richter Gedeon Vegyészeti Gyár Rt. | Eljárás sertralin előállítására és az eljárásban alkalmazott intermedier |
| IN191358B (enExample) | 1998-01-16 | 2003-11-29 | Pfizer Prod Inc | |
| US6054614A (en) | 1998-04-23 | 2000-04-25 | Ciba Specialty Chemicals Corporation | Process for the preparation of tetralone imines for the preparation of active pharmaceutical compounds |
| HU226424B1 (en) * | 1998-05-05 | 2008-12-29 | Egis Gyogyszergyar Nyrt | Process for producing enantiomer mixture for preparation of sertraline |
| IL132500A0 (en) * | 1998-10-29 | 2001-03-19 | Pfizer Prod Inc | Stereoselective microbial reduction of a racemic tetralone |
-
2000
- 2000-01-04 IN IN12MU2000 patent/IN187170B/en unknown
- 2000-11-10 US US09/709,812 patent/US6506940B1/en not_active Expired - Fee Related
-
2001
- 2001-01-01 WO PCT/IN2001/000001 patent/WO2001049638A2/en not_active Ceased
- 2001-01-01 CH CH01496/01A patent/CH692620A5/de not_active IP Right Cessation
- 2001-01-01 AU AU35979/01A patent/AU3597901A/en not_active Abandoned
- 2001-01-04 IT IT2001MI000011A patent/ITMI20010011A1/it unknown
- 2001-07-03 BE BE2001/0440A patent/BE1013214A6/fr not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US6506940B1 (en) | 2003-01-14 |
| WO2001049638A2 (en) | 2001-07-12 |
| CH692620A5 (de) | 2002-08-30 |
| ITMI20010011A1 (it) | 2002-07-04 |
| IN187170B (enExample) | 2002-02-23 |
| WO2001049638A3 (en) | 2001-12-06 |
| AU3597901A (en) | 2001-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BE1006426A6 (fr) | Procede de preparation de la n-methyl-3-phenyl-3-[4-(trifluoromethyl)-phenoxy]-propylamine et de ses sels d'addition d'acide. | |
| US10058849B2 (en) | Metal complex catalyst, preparation method thereof, and use thereof in preparing D,L-menthol | |
| US6506940B1 (en) | Process for converting stereoisomers of sertraline into sertraline | |
| FR2832146A1 (fr) | Base libre de tamsulosine racemique et ses procedes de preparation | |
| WO2005077890A1 (fr) | Nouveau procede de synthese du (7-methoxy-1-naphtyl)acetonitrile et application a la synthese de l’agomelatine | |
| AP956A (en) | Novel process for preparing ketimine. | |
| US6593496B1 (en) | Process for preparing sertraline from chiral tetralone | |
| CA2820192C (fr) | Procede de synthese enzymatique de la (7s)-1-(3,4-dimethoxy bicyclo[4.2.0]octa-1,3,5-triene 7-yl) n-methyl methanamine, et application a la synthese de l'ivabradine et de ses sels | |
| US6846957B2 (en) | Synthesis of 3-aminomethyl-1-propanol, a fluoxetine precursor | |
| EP0091385A1 (fr) | Procédé de préparation de p-hydroxybenzylnitriles ou p-hydroxybenzylamines | |
| EP0303545B1 (fr) | Procédé pour la préparation de phényléthanolaminotétralines | |
| US7262327B2 (en) | Recycling process for preparing sertraline | |
| CH642373A5 (fr) | Compose pyrannique, procede pour sa preparation et son utilisation a titre d'intermediaire de synthese. | |
| EP0478977B1 (fr) | Procédé pour la préparation d'oléfines polyinsaturées | |
| US20080114071A1 (en) | Processes for preparing sertraline | |
| FR1464505A (fr) | Procédé pour la préparation du 1, 3-cyclohexadiényl-carbonitrile | |
| US20070213562A1 (en) | Recycling process for preparing sertraline | |
| CH641764A5 (fr) | Sels d'imidoesters et procede de synthese de 2-naphtalene-ethanimidamide n,n'-disubstitues a partir desdits sels. | |
| CH306902A (fr) | Procédé de préparation du w-1-(4-biphénylyl)-2-dichloracétamido-propane-diol-1,3. | |
| BE527522A (enExample) | ||
| CH612413A5 (en) | 3-Aminoalkyl 2-aryl bicyclo-(2,2,0)-octanes | |
| BE560811A (enExample) | ||
| BE441883A (enExample) | ||
| BE532238A (enExample) | ||
| CH617664A5 (en) | Process for the preparation of benzobicycloalkeneamines and related compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RE | Patent lapsed |
Effective date: 20030731 |